# Jack Mardekian

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/jack-mardekian/

## Facts

| Field | Value |
| --- | --- |
| Citations | 5,831 |
| Field | Atrial Fibrillation Management and Outcomes |
| h-index | 42 |
| i10-index | 125 |
| Last Known Institution | Pfizer (United States) |
| OpenAlex ID | https://openalex.org/A5054571533 |
| ORCID iD | 0000-0003-4851-5161 |
| Works | 360 |

## Researcher papers

- [Sertraline in Children and Adolescents With Obsessive-Compulsive Disorder](https://scholariq.org/papers/sertraline-in-children-and-adolescents-with-obsessive-compulsive-disorder/)
- [Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients](https://scholariq.org/papers/effectiveness-and-safety-of-oral-anticoagulants-among-nonvalvular-atrial/)
- [Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin](https://scholariq.org/papers/real-world-comparison-of-major-bleeding-risk-among-non-valvular-atrial/)
- [Propensity score matching and inverse probability of treatment weighting to address confounding by indication in comparative effectiveness research of oral anticoagulants](https://scholariq.org/papers/propensity-score-matching-and-inverse-probability-of-treatment-weighting-to/)
- [Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in “real-world” clinical practice](https://scholariq.org/papers/effectiveness-and-safety-of-apixaban-versus-warfarin-in-non-valvular-atrial/)
- [Comparative effectiveness of first-line palbociclib plus letrozole versus letrozole alone for HR+/HER2− metastatic breast cancer in US real-world clinical practice](https://scholariq.org/papers/comparative-effectiveness-of-first-line-palbociclib-plus-letrozole-versus/)
- [Healthcare utilization and costs in diabetes relative to the clinical spectrum of painful diabetic peripheral neuropathy](https://scholariq.org/papers/healthcare-utilization-and-costs-in-diabetes-relative-to-the-clinical-spectrum/)
- [Reverse Engineering and Evaluation of Prediction Models for Progression to Type 2 Diabetes](https://scholariq.org/papers/reverse-engineering-and-evaluation-of-prediction-models-for-progression-to-type/)
- [Major bleeding risk among non‐valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban or warfarin: a “real‐world” observational study in the United States](https://scholariq.org/papers/major-bleeding-risk-among-non-valvular-atrial-fibrillation-patients-initiated-on/)
- [Validity of 24-h recall ratings of pain severity: Biasing effects of “Peak” and “End” pain](https://scholariq.org/papers/validity-of-24-h-recall-ratings-of-pain-severity-biasing-effects-of-peak-and-end/)
- [Incremental health care resource utilization and expenditures associated with autosomal dominant polycystic kidney disease](https://scholariq.org/papers/incremental-health-care-resource-utilization-and-expenditures-associated-with/)

## Researcher topics

- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)
- [Venous Thromboembolism Diagnosis and Management](https://scholariq.org/topics/venous-thromboembolism-diagnosis-and-management/)
- [Opioid Use Disorder Treatment](https://scholariq.org/topics/opioid-use-disorder-treatment/)
- [Health Systems, Economic Evaluations, Quality of Life](https://scholariq.org/topics/health-systems-economic-evaluations-quality-of-life/)
- [Pain Management and Opioid Use](https://scholariq.org/topics/pain-management-and-opioid-use/)

## Researcher university

- [Pfizer (United States)](https://scholariq.org/institutions/pfizer-united-states/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.